Doravirine plus dolutegravir switch for people with HIV
Treatments studied
Part of Infections clinical trials.
This Phase 3 study tests whether switching from a three-drug HIV regimen to a two-drug regimen (doravirine plus dolutegravir) can keep your virus levels controlled. It may help people who are stable on their current treatment explore a simpler switch under close monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and have HIV-1
- You’ve been on a stable, suppressive three-drug HIV treatment for at least 6 months
- You do not have known resistance to doravirine (DOR) or dolutegravir (DTG)
- Your recent labs are safe enough: hemoglobin at least 9, platelets at least 80, and kidney function (creatinine clearance) at least 30
- You are not pregnant or breastfeeding
- If you’re able to become pregnant, you use reliable birth control as required by the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two HIV medicines, doravirine and dolutegravir, to see which works better for people who have never taken HIV treatment before. If you qualify, you would be randomly assigned to one of the two medications.
This trial is for people with HIV who are not responding well to the drug dolutegravir (DTG). It tests if switching to a different drug, darunavir/ritonavir (DRV/r), works better than continuing DTG when resistance has developed.
This trial compares a two-drug regimen of doravirine and lamivudine to another two-drug regimen of dolutegravir and lamivudine for people with HIV who have had a suppressed viral load for at least 24 months. The goal is to see if the newer combination works as well as the current one.
This study collects data from HIV patients who start treatment with a two-drug combination of dolutegravir and lamivudine, either as their first treatment or after switching from a three-drug regimen.
This trial tests better ways to manage HIV when the virus becomes resistant to dolutegravir (DTG), a key medicine. It is for people with high viral load despite being on DTG for at least six months.
This study sees if it's safe to switch your current HIV medication to a two-pill combo (dolutegravir and lamivudine) if you are also taking medication for opioid addiction. It aims to make treatment simpler and more convenient.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.